Penn Gene-Editing Spinout iEcure Receives Rare Pediatric Disease Designation from FDA for Lead Drug Candidate
iEcure is developing the new drug candidate, GTP-506, as a treatment for a rare genetic condition caused by a genetic defect in a liver enzyme responsible for detoxification of ammonia.
Penn Spinout REGENXBIO Inc. Enters Commercial Phase; Focuses Gene Therapy on Common Cause of Blindness
Regenxbio's gene therapy would eliminate the need for wet AMD patients to visit their doctor every few months to receive a needle in their eye to treat their condition.
Regenxbio, a gene therapy company founded through collaboration with PCI, opened a new facility at its Maryland campus.
Penn’s Innovation in Process Science combines with CBM manufacturing capability to develop large-scale gene therapy manufacturing capacity, testing, and analytics
The G2 Bio Companies, founded by James M. Wilson and the late Tachi Yamada, launched with a $200 million investment commitment from the global investment firm Temasek.
Penn’s gene therapy program has signed a 150,000 sq ft lease at a former GlaxoSmithKline property in King of Prussia
“The Penn transaction is an indicator that the entire region is benefiting from the research being done in our world-renowned institutions.”